Tripep AB expands the new issue of shares and raises another SEK 2 million


Tripep AB expands the new issue of shares and raises another SEK 2 million 

The Board of  Directors of Tripep AB has, based on the authorization by the AGM,
resolved to raise another SEK 2 million through the issue of 4,000,000 shares at
SEK 0.50 per share. 

The new issue is made without preferential rights for existing shareholders and
has been subscribed by existing shareholders. The proceeds will be used as
working capital.

The issue of 4,000,000 shares will increase the number of shares in the company
to 33,575,314. 


For more information, please contact:

Anders Vahlne, CEO & Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se



About Tripep
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal® and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB. For more information, please refer to the
company's website:www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.

Pièces jointes

07212109.pdf
GlobeNewswire